These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 19192475

  • 1. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [Abstract] [Full Text] [Related]

  • 3. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [Abstract] [Full Text] [Related]

  • 6. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [Abstract] [Full Text] [Related]

  • 7. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH, Lin SH, Jang FL.
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
    Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA, Carlson BX, Berman RM.
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
    [Abstract] [Full Text] [Related]

  • 9. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [Abstract] [Full Text] [Related]

  • 10. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC.
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [Abstract] [Full Text] [Related]

  • 11. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
    Chen SJ, Hsiao YL, Shen TW, Chen ST.
    J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
    [Abstract] [Full Text] [Related]

  • 12. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN.
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H.
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [Abstract] [Full Text] [Related]

  • 14. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R.
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [Abstract] [Full Text] [Related]

  • 16. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN.
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [Abstract] [Full Text] [Related]

  • 17. A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
    Reimherr FW, Martin ML, Eudicone JM, Marchant BK, Tran QV, Pikalov A, Marcus RN, Berman RM, Carlson BX.
    J Clin Psychopharmacol; 2010 Jun; 30(3):300-5. PubMed ID: 20473067
    [Abstract] [Full Text] [Related]

  • 18. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H.
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [Abstract] [Full Text] [Related]

  • 19. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [Abstract] [Full Text] [Related]

  • 20. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
    Schüle C, Baghai TC, Eser D, Hecht S, Hermisson I, Born C, Häfner S, Nothdurfter C, Rupprecht R.
    World J Biol Psychiatry; 2007 Jan; 8(2):112-22. PubMed ID: 17455104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.